
Venture capital
Curie.Bio
Curie.Bio is a venture firm for drug discovery that funds founders developing new therapeutics and supplies a large in-house group of experienced scientists and operators alongside the capital.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is Curie.Bio right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (SEC adviser filings). Values are the gross assets each filing reports, not fund sizes.
Latest investments
Rounds Curie.Bio joined, from press and the firm’s own posts.
Every round Curie.Bio joined
Round sizes, Curie.Bio’s role and who invested alongside.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet Curie.Bio
Events where Curie.Bio’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
Curie.Bio is based in Cambridge, United States.
5 fund vehicles are on public registers (SEC adviser filings), including CURIE BIO SERIES A FUND I, L.P., CURIE BIO SEED FUND II, L.P. and CURIE BIO SEED FUND I, L.P.
Funds therapeutic programs at any modality from concept through the clinic via two vehicles: one for preclinical milestones and one for clinical proof of concept. Beyond money, it embeds experienced drug developers who plan R&D, run experiments, and help raise follow-on capital. From the firm’s own website.
$5M to $15M per investment, according to the firm’s own website.
Know before Curie.Bio’s next round is announced.
PRO tracks Curie.Bio’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.